This Market Spotlight report covers the Opioid-Induced Constipation market, comprising key marketed and pipeline drugs, clinical trials, upcoming and regulatory events, patent information, probability of success, epidemiology data, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Takeaways

• The approved drugs in the opioid-induced constipation (OIC) space predominantly target opioid receptors, with the exception of Amitiza, a type-2 chloride channel activator. All of the marketed drugs are administered via the oral route, with one product also being available in a subcutaneous formulation.
• The majority of industry-sponsored drugs in active clinical development for OIC are in Phase II, with only one drug in Phase III. Therapies in mid-to-late-stage development for OIC target opioid receptors and guanylyl cyclase c receptor. These therapies are administered via the oral route.
• The overall likelihood of approval of a Phase I gastroenterology (non inflammatory bowel disease)-other asset is 23.9%, and the average probability a drug advances from Phase III is 66.7%. Drugs, on average, take 10.0 years from Phase I to approval, compared to 9.9 years in the overall gastroenterology (non inflammatory bowel disease) space.
• There have been only three licensing agreements involving OIC drugs during 2014–19. The largest deal was the exclusive license agreement signed in April 2019 between Shionogi and BioDelivery Sciences, pursuant to which BioDelivery Sciences gained full rights to commercialize Symproic tablets 0.2 mg in the US for the treatment of OIC in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer.
• The distribution of clinical trials across Phase I–IV indicates that the majority of trials for OIC have been in the late phases of development, with 60% in Phase III–IV, and 40% in Phase I–II.
• Clinical trial activity in the OIC space is dominated by completed trials. Progenics Pharmaceuticals has the highest number of completed trials for OIC, with 13 trials.
• Progenics Pharmaceuticals leads the industry sponsors with the highest number of clinical trials for OIC, followed by Pfizer.